Back to results
US 12,708,617 B2Granted
Amorphous kinase inhibitor formulations and methods of use thereof
AssigneeDeciphera Pharmaceuticals, LLC
InventorsMichael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Life of this patent
Estimating the term…
Abstract
Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.
Claims1
A method of treating gastrointestinal stromal tumors in a patient in need thereof, comprising administering to the patient, once daily, one or more pharmaceutically acceptable tablets for orally delivering a compound represented by Formula (I):
- wherein each pharmaceutically acceptable tablet comprises:
- (i) a solid dispersion having 50 mg of the compound wherein the compound is present in amorphous form and 150 mg hydroxypropyl methyl cellulose acetate succinate;
- (ii) 179 mg microcrystalline cellulose;
- (iii) 179 mg lactose or a hydrate thereof;
- (iv) 30 mg crospovidone;
- (v) 6 mg of silicon dioxide;
- and
- (vi) 6 mg of magnesium stearate.
5 more elements
Dependencies are inferred from the claim text.